# Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

> **NCT01479374** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 397 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** AL-4943A ophthalmic solution
- **DRUG:** AL-4943A vehicle
- **DRUG:** Olopatadine hydrochloride ophthalmic solution, 0.2%

## Key facts

- **NCT ID:** NCT01479374
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479374, "Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01479374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*